Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Liver Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
13 drugs · 38 active trials
14 drugs · 333 active trials
Outside the funnel: Phase not stated 3. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 15 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Sintilimab | Phase 3 | Phase 3 | 25 | 15 | 12 | 54 | 0 | — | — | Feb 11, 2019 |
| Tislelizumab | Phase 3 | Phase 3 | 18 | 10 | 4 | 37 | 0 | — | — | Dec 18, 2017 |
| Gemcitabine | Phase 3 | Phase 3 | 15 | 8 | 11 | 49 | 0 | — | — | 1998-08 |
| Cisplatin | Phase 3 | Phase 3 | 13 | 7 | 17 | 48 | 0 | — | — | 1994-05 |
| Camrelizumab | Phase 3 | Phase 3 | 12 | 7 | 6 | 29 | 0 | — | — | 2016-10 |
| Oxaliplatin | Phase 3 | Phase 3 | 10 | 4 | 10 | 44 | 0 | — | — | 1998-04 |
| Capecitabine | Phase 3 | Phase 3 | 8 | 3 | 8 | 35 | 0 | — | — | 2001-07 |
| Adebrelimab | Phase 3 | Phase 3 | 7 | 5 | 1 | 11 | 0 | — | — | Aug 2, 2022 |
| Toripalimab | Phase 3 | Phase 3 | 6 | 2 | 5 | 25 | 0 | — | — | Mar 5, 2019 |
| Fluorouracil | Phase 3 | Phase 3 | 5 | 2 | 6 | 30 | 0 | — | — | 1998-03 |
| FOLFOX Regimen | Phase 3 | Phase 3 | 5 | 3 | 4 | 12 | 0 | — | — | Mar 1, 2017 |
| Irinotecan | Phase 3 | Phase 3 | 4 | 2 | 3 | 15 | 0 | — | — | 1998-04 |
| Carboplatin | Phase 3 | Phase 3 | 3 | 0 | 6 | 21 | 0 | — | — | 1992-10 |
| Nab-paclitaxel | Phase 3 | Phase 3 | 3 | 3 | 1 | 8 | 0 | — | — | 2015-04 |
| Sunitinib | Phase 3 | Phase 3 | 2 | 1 | 2 | 13 | 0 | — | — | 2006-02 |
| Dexamethasone | Phase 3 | Phase 3 | 2 | 2 | 1 | 10 | 0 | — | — | 2003-08 |
| Thalidomide | Phase 3 | Phase 3 | 1 | 0 | 4 | 12 | 0 | — | — | 2000-05 |
| Pegargiminase | Phase 3 | Phase 3 | 1 | 1 | 2 | 9 | 0 | — | — | 2002-09 |
| FOLFOX-4 Regimen | Phase 3 | Phase 3 | 1 | 1 | 3 | 7 | 0 | — | — | 2014-04 |
| Metformin | Phase 3 | Phase 3 | 1 | 1 | 2 | 7 | 0 | — | — | 2014-04 |
| Serplulimab | Phase 3 | Phase 3 | 1 | 1 | 1 | 4 | 0 | — | — | Sep 24, 2019 |
| Enzalutamide | Phase 3 | Phase 3 | 1 | 0 | 1 | 3 | 0 | — | — | Nov 9, 2015 |
| Peginterferon Alfa-2b | Phase 3 | Phase 3 | 1 | 0 | 1 | 2 | 0 | — | — | 2002-03 |
| Abiraterone | Phase 3 | Phase 3 | 1 | 0 | 1 | 1 | 0 | — | — | Jul 30, 2026 |
| Erlotinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 9 | 0 | — | — | 2005-10 |
| Sirolimus | Phase 3 | Phase 3 | 0 | 0 | 3 | 9 | 0 | — | — | 1996-12 |
| Mitomycin | Phase 3 | Phase 3 | 0 | 0 | 2 | 8 | 0 | — | — | Dec 15, 1999 |
| Arsenic Trioxide | Phase 3 | Phase 3 | 0 | 0 | 1 | 5 | 0 | — | — | 2001-03 |
| Bortezomib | Phase 3 | Phase 3 | 0 | 0 | 1 | 5 | 0 | — | — | 2004-03 |
| Temsirolimus | Phase 3 | Phase 3 | 0 | 0 | 1 | 5 | 0 | — | — | Sep 8, 2009 |
| Idarubicin | Phase 3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — | — | 2009-12 |
| Pazopanib | Phase 3 | Phase 3 | 0 | 0 | 1 | 3 | 0 | — | — | Dec 6, 2006 |
| Aspirin | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2013-08 |
| Linifanib | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2007-09 |
| Tamoxifen | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 1994-05 |
| Adjuvant Chemotherapy | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2016-01 |
| Megestrol | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2002-05 |
| Zoledronic Acid | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | May 10, 2023 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.